Your browser doesn't support javascript.
loading
Efficacy and safety of hypofractionated radiotherapy versus conventional fractionated radiotherapy in diffuse intrinsic pontine glioma: A systematic review and meta-analysis.
Viani, Gustavo A; Gouveia, Andre G; Arcidiacono, Fabio; Marta, Gustavo N; Hamamura, Ana Carolina; Anselmo, Paola; Barbosa, Felipe S; Moraes, Fabio Y.
Afiliación
  • Viani GA; Department of Medical Imagings, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, Brazil.
  • Gouveia AG; Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  • Arcidiacono F; Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  • Marta GN; Division of Radiation Oncology, Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
  • Hamamura AC; Radiotherapy Oncology Centre, "S. Maria" Hospital, Terni, Italy.
  • Anselmo P; Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  • Barbosa FS; Radiation Oncology Department, Hospital Sirio Libanês, São Paulo, Brazil.
  • Moraes FY; Post-Graduation Program, Department of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil.
Rep Pract Oncol Radiother ; 29(3): 309-317, 2024.
Article en En | MEDLINE | ID: mdl-39144263
ABSTRACT

Background:

Diffuse intrinsic pontine glioma (DIPG) stands as the predominant type of brainstem glioma. It is characterized by a notably brief median survival period, with the majority of patients experiencing disease progression within six months following radiation therapy. This systematic review and meta-analysis aims to assess the efficacy and safety of hypofractionated radiotherapy (HFRT) compared to conventionally fractionated radiotherapy (CFRT) in DIPG treatment. Materials and

methods:

A systematic literature search was conducted in four databases, and relevant studies comparing HFRT and CFRT in DIPG were included. Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), and treatment-related toxicities. Statistical analysis was performed using random-effects models with heterogeneity assessment.

Results:

Five studies met the inclusion criteria, comprising 518 patients. No significant difference in one-year OS was observed between HFRT and CFRT (29% vs. 22%, p = 0.94). The median OS was similar in both treatment groups (9.7 vs. 9.3 months, p = 0.324). Similarly, no significant difference in one-year PFS was found between HFRT and CFRT (19.8% vs. 16.6%, p = 0.82), with comparable median PFS (9.3 vs. 9.4 months, p = 0.20). In meta-regression analysis, there was no association of chemotherapy (p > 0.05) or radiation biologically effective dose (BED) (p > 0.05) regarding OS or PFS outcomes. There were no significant differences in treatment-related toxicities.

Conclusions:

HFRT yields one-year OS and PFS rates similar to CFRT in DIPG, with no significant differences in treatment-related toxicities. Chemotherapy and BED did not affect OS or PFS.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Rep Pract Oncol Radiother Año: 2024 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Rep Pract Oncol Radiother Año: 2024 Tipo del documento: Article País de afiliación: Brasil
...